Dr. Zylberberg is Recognized as a Leader in the Cell and Gene Therapy Industry

Every year, the Medicine Maker, a global publication with a focus on the people that drive the development of small and large molecule drugs as well as advanced therapies, compiles a list of pioneers and influencers advancing the knowledge frontier, driving clinical application, and fostering industry growth. The annual Medicine Maker Power List is compiled on the basis of reader votes as well as an expert panel comprised of influencers in the biopharmaceutical industry. For the complete 2019 Power List, click here.

This year in particular, the list shines a light on the emergence and growth of advanced therapies, awarding talented scientists and entrepreneurs from the cell and gene space. This year’s list features Akron Biotech CEO Claudia Zylberberg, PhD as one of 25 Business Captains, alongside the CEOs of Sanofi, Novartis, GSK, Merck, and more. She joins Dr. Massimo Dominici, MD (Italy) and Dr. Bruce Levine, PhD (USA) as leaders of the International Society for Cell and Gene Therapy (ISCT) recognized for their thought leadership. See here for ISCT’s announcement.

Dr. Zylberberg’s recognition reflects the continued growth and promise of cell and gene therapy, and acknowledges the integral role that ancillary materials play in the development of safe and effective therapies. Because advanced therapies cannot be sterilized, it is critical that everything used to produce them is sterile. Akron has long been committed to manufacturing these critical materials at the highest of standards to ensure the successful development of advanced therapies. From the entire Akron team, we are incredibly proud.